Codiak BioSciences, Inc. announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13.
A webcast of the virtual fireside chat with H.C. Wainwright research analyst Mike King will be available on demand as of 7:00 a.m. EST on Monday, January 10 on the Investors & Media section of the Codiak website at www.codiakbio.com. The archived replay will be available for approximately 30 days following the event.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of diseases, spanning oncology, neuro-oncology, infectious disease and rare disease.
Investor Contact: Christopher Taylor VP, Investor Relations and Corporate Communications T: 617-949-4220 E: investor@codiakbio.com Media Contact: Lindy Devereux Scient PR T: 646-515-5730 E: media@codiakbio.com
